Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Endo Pharmaceuticals Inc. v. Actavis LLC
Case Number:
18-1054
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
May 03, 2019
Fed. Circ. Upholds Opana Patent Amid Generic Challenge
The Federal Circuit on Friday upheld the validity of a patent related to Endo Pharmaceuticals' opioid painkiller Opana ER, finding generic-drug maker Teva Pharmaceuticals had not shown the invention was obvious.
-
December 06, 2018
Fed. Circ. Asks Whether Endo's Opioid Patent Was Obvious
Actavis LLC and Endo Pharmaceuticals Inc. faced questions from a Federal Circuit panel on Thursday regarding whether someone of ordinary skill could successfully develop Endo's opioid painkiller Opana ER, amid Actavis' appeal of a ruling that Endo's Opana patent is valid.